Practice Resources
Practice Resources
Practice
Resources
Practice Resources
Download information about cystinosis and supporting eye health with CYSTARAN for your practice and your patients:
Resources to Share With Your Patients
External Resources
Cystinosis Reasearch Foundation
Cystinosis Reasearch Network
Offices of Rare Disease Research
Genetics Home Reference
National Eye Institute
National Kidney Foundation
National Organization for Rare Disorders
INDICATION & IMPORTANT SAFETY INFORMATION
CYSTARAN® (CYSTEAMINE OPHTHALMIC SOLUTION) 0.44% is a cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis.
IMPORTANT SAFETY INFORMATION
- To minimize contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use.
- There have been reports of benign intracranial hypertension (or pseudotumor cerebri) associated with oral cysteamine treatment that has resolved with the addition of diuretic therapy. There have also been reports assoc